Last updated on December 2019

Efficacy and Safety of Filgotinib in the Treatment of Small Bowel Crohn's Disease (SBCD)


Brief description of study

The primary objective of this study is to evaluate the efficacy of filgotinib, when compared to placebo, in establishing clinical remission in participants with Crohn's disease involving the small bowel. Participants will have the option to enter a separate long-term extension study if they meet eligibility requirements.

Clinical Study Identifier: NCT03046056

Find a site near you

Start Over